Conduit Pharmaceuticals Quote - CDT

Professional-Grade Tools, for Individual Investors.

Premium

Current Price

0.1119

Bid

0.1118

Ask

0.1119

Volume

486,307,849

0.1076 Day's Range 0.1579

0.0789 52 Week Range 7.7509

Market Cap

10.743M

Previous Close

0.0923

Open

0.14465

Last Trade

200

0.1119

Last Trade Time

10:05:26

Financial Volume

US$ 61,500,339

VWAP

0.126464

Average Volume (3m)

13,582,592

Shares Outstanding

96,004,699

Dividend Yield

PE Ratio

-267.04

Earnings Per Share (EPS)

-0.06

Revenue

Net Profit

-6.06M

Conduit Pharmaceuticals, Inc. is a disease agnostic life science company. The Company is engaged in the development and commercialization of clinical assets to address the unmet medical needs of patients. The Company's licensed clinical assets are focused on idiopathic male infertility and autoimmun... Conduit Pharmaceuticals, Inc. is a disease agnostic life science company. The Company is engaged in the development and commercialization of clinical assets to address the unmet medical needs of patients. The Company's licensed clinical assets are focused on idiopathic male infertility and autoimmune diseases or immunodeficient conditions like uveitis, preterm labor, renal transplant rejection and Hashimoto's Thyroiditis. The Company's asset pipeline includes AZD1656 (a Glucokinase Activator), and AZD5904 (a Myeloperoxidase Inhibitor). AZD1656 is a glucokinase activator used in diabetes mellitus. It is used as a treatment option for Hashimoto's Thyroiditis (HT) and Graves' disease, including investigating any negative side effects of the use of AZD1656 as compared with treatment options for Hashimoto's Thyroiditis and Graves' disease. AZD5904 includes a potent, irreversible inhibitor of human myeloperoxidase (MPO), that has the potential to treat Idiopathic Male Infertility (IMI). Show more

Sector

Pharmaceutical Preparations

Industry

Pharmaceutical Preparations

Website

www.conduitpharma.com

Headquarters

Wilmington, Delaware, USA

Founded

Conduit Pharmaceuticals Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker CDT. The last closing price for Conduit Pharmaceuticals was US$0.09. Over the last year, Conduit Pharmaceuticals shares have traded in a share price range of US$ 0.0789 to US$ 7.7509.

Conduit Pharmaceuticals currently has 96,004,699 shares outstanding. The market capitalization of Conduit Pharmaceuticals is US$8.86 million. Conduit Pharmaceuticals has a price to earnings ratio (PE ratio) of -267.04.

Conduit Pharmaceuticals Receives Further Patent Approval For Lead Asset Targeting Autoimmune Disorders

NAPLES, Fla. and CAMBRIDGE, United Kingdom, Nov. 21, 2024 (GLOBE NEWSWIRE) -- Conduit Pharmaceuticals Inc. (Nasdaq: CDT) ("Conduit Pharmaceuticals" or "Conduit" or the “Company”) today announced...

Conduit Pharmaceuticals Announces Appointment of Simon Fry to Board of Directors

Conduit Pharmaceuticals strengthens its Board of Directors with the addition of Simon Fry, a seasoned investment banking executive with over 30 years of experience in asset management, capital...

Conduit Pharmaceuticals Announces Debt Restructuring and Additional Notes

SAN DIEGO and LONDON, Nov. 01, 2024 (GLOBE NEWSWIRE) -- Conduit Pharmaceuticals Inc. (Nasdaq: CDT) (“Conduit” or the “Company”), today announced the restructuring of a portion of its financial...

Conduit Pharmaceuticals to Present at the H.C. Wainwright 26th Annual Global Investment Conference

SAN DIEGO and LONDON, Aug. 28, 2024 (GLOBE NEWSWIRE) -- Conduit Pharmaceuticals Inc. (Nasdaq: CDT) (“Conduit” or the “Company”), today announced it will be participating in the H.C. Wainwright...

Conduit Pharmaceuticals Selects Initial Indications for Lead Clinical Candidate Targeting Autoimmune Disorders

Conduit Pharmaceuticals announces plans to initiate Phase 2a trials in both systemic lupus erythematosus and ANCA-associated vasculitis for its lead clinical candidate, AZD1656AZD1656, a HK-4...

Conduit Pharmaceuticals Enters into Exclusive License Agreement with AstraZeneca for Multiple Assets to Advance Potential First-in-Class Treatments

Conduit Pharmaceuticals enters into exclusive license agreement with AstraZeneca for HK-4 Glucokinase activators AZD1656 and AZD5658 targeting autoimmune indications and myeloperoxidase inhibitor...

Period	Change	Change %	Open	High	Low	Avg. Daily Vol	VWAP
1	0.0167	17.5420168067	0.0952	0.1579	0.0826	7193928	0.09040366	CS
4	0.0019	1.72727272727	0.11	0.1579	0.0789	8028650	0.10219804	CS
12	-0.0286	-20.3558718861	0.1405	0.1579	0.0789	13582592	0.11367299	CS
26	-2.8181	-96.180887372	2.93	3.28	0.0789	12167759	0.1519799	CS
52	-1.1981	-91.4580152672	1.31	7.7509	0.0789	6201397	0.18343472	CS
156	-12.4881	-99.1119047619	12.6	12.89	0.0789	5411918	0.21275927	CS
260	-12.4881	-99.1119047619	12.6	12.89	0.0789	5411918	0.21275927	CS

Most Active
% Gainers
% Losers

Symbol	Price	Vol.
WORXSCWorx Corporation	US$ 1.93 (96.94%)	103.79M
CRNCCerence Inc	US$ 5.0099 (77.66%)	31.16M
BDRXBiodexa Pharmaceuticals PLC	US$ 6.8101 (76.89%)	1.49M
IBGInnovation Beverage Group Limited	US$ 1.10 (39.03%)	6.22M
SPAISafe Pro Group Inc	US$ 4.37 (36.56%)	38.23M
PYXSPyxis Oncology Inc	US$ 2.06 (-46.07%)	9.15M
KURAKura Oncology Inc	US$ 9.865 (-37.99%)	7.4M
BLRXBioLineRx Ltd	US$ 0.3585 (-34.24%)	5.6M
GLXGGalaxy Payroll Group Ltd	US$ 2.60 (-33.50%)	387.24k
SHOTWSafety Shot Inc	US$ 0.1001 (-33.27%)	2.5k
CDTConduit Pharmaceuticals Inc	US$ 0.111999 (21.34%)	486.12M
NVDANVIDIA Corporation	US$ 143.9509 (-1.33%)	198.63M
AKTSAkoustis Technologies Inc	US$ 0.0999 (14.70%)	181.9M
ELABElevai Labs Inc	US$ 0.0202 (-5.61%)	135.79M
WORXSCWorx Corporation	US$ 1.93 (96.94%)	103.79M